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Osteosarcoma is a highly invasive bone malignancy in which metastasis accounts for
the vast majority of death and morbidity in patients. Understanding the mechanisms
controlling metastasis is essential for improving patient survival in this disease. In order to
improve the clinical outcomes for patients with poor prognosis, it is urgent to find new
therapeutic targets to block metastasis in this disease. Recent studies have shown that
Metadherin (MTDH) plays an essential role in mediating tumorigenesis and metastasis in a
variety of human cancers. Our study assessed the role of MTDH in osteosarcoma metastasis
and elucidated the mechanisms underlying its metastasis-promoting activity.
To evaluate the expression of MTDH in primary and metastatic lesions of
osteosarcoma, two tissue microarrays containing patient-derived primary and metastatic
tumor specimens were examined by immunohistochemical staining with anti-MTDH
antibody. We also examined MTDH in a cDNA array expression database made from
pretreatment diagnostic biopsies of high-grade osteosarcoma patients to further assess the
correlation between MTDH expression and clinical outcome. We used western blot, qPCR,
and flow cytometry to measure the expression of MTDH in a panel of osteosarcoma cell
lines. In parallel experiments we used MTDH-specific shRNA to reduce endogenous MTDH
expression, and blocked cell surface MTDH by anti-MTDH antibodies. The impact of
MTDH inhibition was assessed in vitro using transwell migration assays and matrigel
vi

invasion assays. In addition, we developed an orthotopic xenograft mouse model to study the
relationship between MTDH expression and osteosarcoma pulmonary metastasis. To
investigate the role of MTDH in cell-extracellular matrix (ECM) interaction and to identify
the extracellular binding partner for cell surface MTDH, a series of adhesion assays were
performed, followed by bidirectional co-immunoprecipitation.
We have demonstrated that MTDH is up-regulated in human osteosarcoma cell lines
and patient-derived specimens compared with normal human osteoblasts. Overexpression of
MTDH is more profound in metastatic lesions compared to primary tumors and is correlated
with poor clinical outcomes in osteosarcoma patients. MTDH knockdown and blockade of
cell surface MTDH significantly reduced migration and invasion in osteosarcoma cells. In
the in vivo experiments, down-regulation of MTDH in osteosarcoma cells delayed primary
tumor growth and prohibited pulmonary metastasis. Both in vitro and in vivo studies
confirmed the critical role of MTDH in the invasive and metastatic capacity of osteosarcoma
cells. More importantly, we have identified the significance of cell surface localization of
MTDH in mediating osteosarcoma motility and invasiveness. We showed that MTDH exists
as a type II membrane protein in osteosarcoma cells and its expression on cell surface is
facilitating cell invasion by means of modulating cell adhesion to the ECM through
interaction with Laminin. In total, these observations establish MTDH as a promising target
for therapeutic interventions in metastatic osteosarcoma. The novel connection between
MTDH and extracellular laminin also establishes a new paradigm for the function of MTDH
in mediating tumor cell metastasis.
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Chapter 1. Introduction
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Biology of Osteosarcoma
Osteosarcoma is the most common type of primary bone cancer in pediatric patients (1).
It derives from primitive mesenchymal stem cells or osteoblasts and is characterized by the
production of neoplastic osteoid or immature bone by tumor cells (2). Osteosarcoma occurs
primarily in growing adolescents and young adults, with a peak incidence in the second
decade of life. Consistent with its high incidence during puberty when bones grow rapidly,
osteosarcoma usually arises from the metaphyseal regions of the long bones such as the distal
femur and proximal tibia (3). As an exceedingly aggressive tumor, osteosarcoma has a high
tendency to spread to distant organs in the body. The lung is the most frequent site for
metastasis, followed by the bones (4). About 15-20% of patients present with overt lung
metastases and nearly all of the remainder have micrometastatic disease at diagnosis (5, 6).
The standard therapy consists of surgical removal of any resectable primary tumor and
metastases, combined with 6-9 months of neoadjuvant and adjuvant chemotherapy. Current
chemotherapy regimens include four agents: doxorubicin (adriamycin), cisplatin, high-dose
methotrexate with leukovorin rescue, and ifosfamide (2). The addition of liposomal muramyl
tripeptide phosphatidylethanolamine (mifamurtide) to therapeutic regimens demonstrated
clinical benefit and has been approved by the European Union to treat high-grade, resectable,
non-metastatic osteosarcoma (7).
Although the modern multimodal therapy yields a survival of approximately 70% for
patients without overt disease at diagnosis, the clinical outcome for metastatic osteosarcoma
remains poor: fewer than 30% of patients presenting with metastases survive 5 years after
initial diagnosis (8). The prognosis for patients with refractory or recurrent disease is even
worse. Since current treatment options for osteosarcoma patients have very limited efficacy
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against recurrent metastatic disease, most studies in this field have been focused on
identifying key regulatory pathways and molecular events that mediate critical steps of
metastasis.
Essential pathways in osteosarcoma metastasis
Migration and Invasion
The process of tumor metastasis involves a complex cascade of events. The first step is
to interact with and migrate through the extracellular matrix (ECM) and basement membrane
that comprise barriers against invading cells. The pivotal role of matrix metalloproteinases
(MMPs) including MMP-2 and MMP-9, as well as other proteases such as m-calpain, has
been repetitively implicated in osteosarcoma metastasis (9-11). Previous studies also
suggested that the Wnt/β-catenin pathway and Src signaling promote metastasis in
osteosarcoma through modulation of tumor cell migratory ability (12). The Notch pathway,
including its major components Notch receptor 1, 2, and the downstream target gene Hes1,
has been recently identified to be important regulator of osteosarcoma invasion (13, 14).
Survival in the bloodstream
After tumor cell invade into the circulatory system, it is essential for disseminated
tumor cells to acquire anoikis resistance in order to survive in the absence of intercellular
adhesions and cell-ECM interactions. Several molecular mechanisms contribute to the
evasion of anoikis in osteosarcoma, including overexpression of specific integrins, Focal
adhesion kinase (FAK)-independent activation of PI3K/Akt signaling, activation of the Src,
NFκB and Wnt/β-catenin pathways, and upregulation of anti-apoptotic genes of the BcL
family (15).
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Extravasation and adherence
The next step of metastasis is to exit the circulatory vessels, invade into the distant
organ, and adapt to the local microenvironment. The process of extravasation and metastatic
colonization are primarily facilitated by proteinases and chemokines (16, 17). Commonly
expressed chemokines in osteosarcoma include CXCR-3 and CXCR-4. Binding of these
chemokines to their ligands, CXCL-9, -10, -11, and -12, which are abundantly expressed in
the lung, not only mediate adherence of circulating tumor cells, but trigger other essential
survival pathways as well (16, 18-24). Ezrin, a membrane-cytoskeleton linker protein
overexpressed in variety of cancers, is associated with a higher risk of metastasis and poor
survival in both animal models and pediatric patients with osteosarcoma (25-27). Previous
studies suggested that ezrin facilitates adherence of metastatic osteosarcoma cells to lung
tissues by mediating membrane organization and interactions between tumors cells and the
lung microenvironment (28). Ezrin also promotes survival and proliferation of the newly
arrived osteosarcoma cells in the lung through β4-integrin mediated activation of the
PI3K/Akt and MAPK survival pathways (17, 22, 25, 26, 29).
Dormancy
It is frequently observed that osteosarcoma patients who present without radiographic
evidence of metastasis at diagnosis develop metastatic relapse within 2-3 years after initial
resection of the primary tumor (30, 31). This phenomenon is likely explained by the
prolonged survival of single cells or micrometastases in the lung environment, which is
defined as dormancy. When being triggered to start proliferating again, theses small lesions
can quickly develop into gross metastases. Despite the clinical significance of tumor
dormancy, the biological processes regulating dormancy and tumor outgrowth from dormant
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state in osteosarcoma are still poorly understood. Previous studies indicated that tumor
dormancy is controlled by overexpression of the anti-apoptotic protein Bcl-xL, α5β1-integrin
mediated activation of NF-κB signaling, and the ratio between ERK and p38-MAPK proteins
(17, 22, 32, 33). Since vascularization is an essential prerequisite for tumor expansion,
metastatic cells usually increase the expression of anti-angiogenic proteins to suppress tumor
outgrowth and maintain dormancy (34, 35). Recent research suggests that ECM, which is the
source of various growth and survival signals, serves as an important mediator of tumor
dormancy for metastatic cells (32, 35). Micrometastases usually remain in the dormant state
in the absence of connection to the ECM in the lung environment, while proper anchorage to
the ECM could activate dormant cells and stimulate them to proliferate via β1-integrin
signaling. Additionally, dormancy has been shown to be related to a subpopulation of cancer
stem-like cells (CSCs) which have the ability to self-renew and populate a growing tumor
(36-40). With increased capacity for DNA repair and upregulation of anti-apoptotic proteins,
CSCs could survive under metabolic and environmental stresses for a long time (41-46).
Neovascularization
Tumor growth and progression are often dependent on a sufficiency of nutrients and
growth factors supplied by the blood vessels. Therefore, neovascularization and aberrant
proliferation are prerequisites for the sustained expansion of metastatic lesions in the lung.
Simultaneous upregulation of a number of pro-angiogenic factors like VEGF, FGF, HGF,
PDGF, TGF- and Ang-1 and downregulation of anti-angiogenic factors such as
thrombospondin-1, PEDF, and troponin I induce rapid neo-angiogenesis (47-51). Elevated
expression of growth factor receptors and proteolytic enzymes, including EGFR, IGF-1R,
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PDGFR, and MMPs, also contributes to survival and proliferation in metastatic osteosarcoma
cells in the lung (52).
Evasion of immune system
Another important feature of the metastatic osteosarcoma cells that survive either in the
circulatory system or at the sites of metastasis is the ability to evade the host immune
surveillance. Downregulation of the cell surface receptor HLA class 1 prevents the tumor
cells from being recognized by the host cytotoxic T-lymphocytes (52, 53). Metastatic
osteosarcoma cells can also modulate the activity of the host immune system by inducing the
expression of a group of immunosuppressive molecules such as IL-10 (22, 54). The Fas/FasL
signaling pathway has also been implicated in immune evasion of osteosarcoma cells.
Impaired downstream signaling of Fas/FasL pathway or downregulation of Fas expression on
the surface of osteosarcoma cells inhibits Fas-induced cell death and prevents the activation
of cytotoxic natural killer cells, resulting in an increase in metastatic potential. In support of
this notion, patient-derived tumor specimens from osteosarcoma pulmonary metastases have
been shown to be Fas-negative, and low Fas expression is associated with worse prognosis
(55-59).
In spite of tremendous past and ongoing efforts, our knowledge of the mechanisms
underlying cell invasion and metastasis in osteosarcoma is still limited. Previous attempts to
target pathways mentioned above have not demonstrated much clinical efficacy and there has
been little improvement in the treatment of metastatic osteosarcoma over the last decade. To
improve the clinical outcomes for patients with poor prognosis, it is urgent to find new
therapeutic targets to block metastasis in this disease. We became interested in metadherin
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(MTDH) because it has emerged in recent years as an oncogene that is critically involved in
tumor pathogenesis and progression.
Molecular Cloning of MTDH
Metadherin (MTDH), also known as astrocyte elevated gene-1 (AEG1) and Lyric, was
first identified in 2002 as a novel late response gene induced by HIV infection or treatment
with TNF-or viral glycoprotein gp120 in primary human fetal astrocytes (60-62). In 2004,
Brown and Ruoslahti named this protein MTDH as they identified its metastasis-promoting
function in mouse breast cancer cell through an in vivo phage screening (63). The mouse-rat
ortholog of MTDH was cloned in the same year as a tight junction protein that co-localizes
with ZO-1 in rat prostate epithelial cells and encodes the lysine-rich CEACAM-1 co-isolated
protein (Lyric) (64). Human MTDH gene contains 12 exons and 11 introns and is located at
chromosome 8q22, a region that is frequently amplified in many cancers (60). The full-length
MTDH cDNA contains 3611 bps (excluding the poly-A tail) and the human mRNA encodes
a single-pass transmembrane protein consisting of 582 amino acid residues with a predicted
molecular mass of 64 kDa (60, 65). Alternative splicing and posttranslational modifications
of MTDH may lead to different molecular weights detected by western blotting, ranging
from 20kDa to 80kDa (64, 66).
MTDH structure and localization
According to BLAST analysis of MTDH, the structure of this gene has no similarity to
any currently known genes (64). Initial protein motif analyses failed to identify any known
functional domains or motifs in MTDH except a putative transmembrane domain (TMD) and
three nuclear localization signals (NLS) (60, 63, 64, 66). The highly hydrophobic TMD,
which is further confirmed by multiple independent protein structure prediction approaches,
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is localized very close to the N-terminal, between 51-72 amino acid residues (67). The
function of the three NLSs, at the locations between 79-91, 432-451, and 561-580 amino acid
residues, was further characterized by Thirkettle and colleagues (68). They found that the
extended NLS-1 (78-130 a.a.) and NLS-3 (546-582 a.a.) are responsible for nucleolar and
nuclear localization of MTDH respectively, and the NLS-2 (415-486 a.a.) ubiquitination
directs the cytoplasmic distribution of MTDH.
The subcellular localization and transmembrane orientation of this molecule have been
a subject of great debate. Initial characterization of MTDH suggested that it localizes
predominantly to the cytoplasm, endoplasmic reticulum, perinuclear region, nucleus, and
inside the nucleolus in various cell types (60, 66, 69). However, immunofluorescence
detection and FACS analysis of non-permeabilized mouse mammary tumor cells revealed
cell surface localization of MTDH (63). The orientation of cell surface MTDH remains
controversial: while most investigators believe that MTDH has a Type Ib topology based on
functional analyses and the C-terminal localization of the experimentally verified NLSs,
Brown and Ruoslahti have demonstrated a type II orientation for MTDH in breast cancer
cells and proposed a putative lung-homing domain (LHD) which they suggested mediates
lung metastasis through interactions with lung endothelial cells (63, 66, 69).
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Figure 1

Figure 1. Schematic diagram of the full-length MTDH protein structure and topology
on membrane. The numbers denote amino acid positions. TMD: transmembrane domain;
NLS: nuclear localization signal; and LHD: lung homing domain.

MTDH in cancer
MTDH is ubiquitously expressed in all human normal tissues at varying levels (60).
However, numerous studies over the past decade have demonstrated that MTDH expression
is significantly upregulated in many types of solid tumors including glioma,
oligodendroglioma, neuroblastoma, melanoma, brain, head and neck, breast, prostate,
esophageal, lung, gastric, renal, liver, and colorectal cancer when compared with normal
tissues (60, 63, 65, 70-84). Consistent with the high incidence of MTDH overexpression in
9

cancer, recent clinical studies have provided convincing evidence of an association between
high MTDH expression level and advanced tumor stage as well as poor patient prognosis (68,
70, 78, 80-83). These observations strongly suggest that MTDH could be employed as a
powerful diagnostic or prognostic marker in a variety of cancer types.
In parallel with evaluation of MTDH as a biomarker for cancer, mounting evidence
from functional studies indicates a pivotal role of MTDH in diverse aspects of tumor
malignancy including aberrant proliferation, angiogenesis, invasion, metastasis, and
chemoresistance (69, 77, 85). In addition to its unique ability to modulate gene expression
changes that are common in cancer, MTDH promotes tumor progression through activation
and integration of multiple pro-tumorigenic signal transduction pathways (65, 67). Ras
signaling increases MTDH expression (86), which subsequently promotes cancer cell growth,
survival, and invasion through the activation of PI3K/Akt (69), NF-κB (87, 88), and Wnt/βcatenin pathways (77). MTDH-induced activation of PI3K/Akt signaling protects cells from
apoptosis and facilitates angiogenesis (85, 89). By activating NFκB and its downstream
targets, MTDH increases proliferation, angiogenesis, inflammation, and invasion in tumor
cells (16, 88). MTDH could also alter expression of a group of genes involved in invasion,
chemoresistance, senescence, and angiogenesis through Wnt/β-catenin pathway (78)
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Figure 2

Figure 2. MTDH promotes tumor progression through the integration of multiple
signaling pathways. Oncogenic Ha-Ras increases MTDH expression through the activation
of the PI3K/Akt pathway, which phosphorylates and inactivates GSK3β, and subsequently
enhances the stabilization and binding of c-Myc to the MTDH promoter. Activation of NFκB
signaling is partially mediated by the direct interaction of MTDH with p65 and CBP. MTDH
activates the Wnt/β-catenin pathway through increasing the activity of MAPK kinases ERK
and p38, which phosphorylates GSK3β and stabilized β-catenin. Furthermore, MTDH
increases the expression of LEF-1, a transcriptional cofactor for β-catenin. The important role
of MTDH in broad spectrum chemoresistance is mediated by many downstream genes that
promote the resistance to multiple chemotherapeutic agents. Reprinted from Hu G et al. Clin
Cancer Res 2009;15:(5615-5620) with permission from American Association for Cancer
Research.
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MTDH and metastasis
As an important mediator of tumor development and progression, the invasionpromoting function of MTDH has been confirmed by multiple studies in various types of
aggressive cancer including glioma, neuroblastoma, prostate cancer, breast cancer,
hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma, and colorectal
carcinoma (63, 70, 73, 74, 78, 84, 90). Upregulation of MTDH leads to elevated expression
of adhesion molecules, which facilitate both the extravasation and intravasation processes of
metastasis. A recent study comparing metastatic potential of HCC cell lines with different
MTDH expression displayed that cells with higher endogenous MTDH levels have better
adhesive ability to microvascular endothelial cells than those with relatively lower MTDH
expression (91). Additionally, MTDH-induced activation and secretion of MMPs, especially
MMP1, MMP2 and MMP9, have been shown to promote metastasis through remodeling and
degradation of ECM (70, 71, 84). In cancers of epithelial origin such as breast cancer and
HCC, MTDH could enhance metastatic spread of tumor cells by inducing the epithelialmesenchymal transition (EMT) process (92, 93).
Another important finding concerning the function of MTDH in metastasis is the
identification of the putative extracellular lung-homing domain through a phage display
experiment conducted in the breast cancer mouse model. It has been shown that
overexpression of MTDH in human embryonic kidney cells enhances their localization to
lung vasculatures. Neutralizing antibodies targeting this specific domain of MTDH displayed
comparable inhibition of experimental pulmonary metastasis as siRNA-mediated MTDH
knockdown in breast cancer cells. Based on these observations, it was postulated that MTDH
favorably promotes pulmonary metastasis as it detects and binds to an unknown marker that
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is primarily expressed on the surface of lung endothelial cells. However, the hypothesis that
MTDH has a binding preference for the lung vascular bed remains questionable. Recent
studies have demonstrated that MTDH not only promotes lung metastasis, but also enhances
metastasis to other organs, such as the bone and brain in breast cancer, and liver in colorectal
cancer (65, 94). To date, the molecular mechanisms of MTDH binding to endothelium
remain elusive.
The role of MTDH in osteosarcoma
The first study to characterize the expression status of MTDH in osteosarcoma was
conducted by Wang and colleagues in 2011(95). They performed immunohistochemical
staining to examine the MTDH expression level in 82 paraffin-embedded surgical specimens,
including 62 osteosarcoma samples and 20 normal bone tissues from patients who had
received neoadjuvant chemotherapy. They found that MTDH was overexpressed in the
majority of osteosarcoma samples assessed while MTDH expression was barely detectable in
normal bone tissues. Spearman correlation analysis based on IHC staining score of theses
specimens indicated that MTDH overexpression is strongly associated with clinical stages,
classification, metastasis, and differentiation. Moreover, the average survival time in the low
MTDH expression group was remarkably longer than that in high MTDH expression
group. The only other report about the function of MTDH in osteosarcoma was focused on
how MTDH mediates chemoresistance (96). It has been shown that MTDH confers
chemoresistance in osteosarcoma cells by regulating ET-1/ETAR signaling pathway in a
PI3K-dependent manner. Due to the lack of knowledge about the role of MTDH in
osteosarcoma metastasis, we decided to focus our efforts on exploring this research topic.
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Goal of dissertation
Osteosarcoma is the most common bone malignancy, causing significant morbidity and
mortality in teenagers and young adults. With current treatment regimens combining
chemotherapy and surgery, osteosarcoma patients with localized disease have a survival rate
that approaches 70%. However, the clinical outcome for metastatic osteosarcoma remains
poor. For patients who suffer from this fatal disease, a better understanding of how their
cancer metastasizes will lead to novel therapeutic approaches that will significantly prolong
their survival and improve the quality of their lives. To address this challenge, it is critical to
identify and characterize promising proteins and key pathways responsible for osteosarcoma
progression and metastasis and to develop their specific inhibitors.
Over the past 10 years, numerous studies have consistently demonstrated that high
expression of MTDH is associated with increased tumor aggressiveness, metastasis, and
decreased patient survival in a variety of human solid tumors. These observations establish
MTDH as a promising target for therapeutic interventions. It will be important to know
which tumors might benefit from such treatments. To date, however, very few studies have
examined the functional role of MTDH in osteosarcoma and our knowledge about how
MTDH expression affects osteosarcoma metastasis is very limited. The first goal of our
research was to confirm the expression status of MTDH in osteosarcoma and to assess its
impact on patient survival. Next, we wanted determine the sub-cellular localization and
transmembrane orientation of MTDH in osteosarcoma. We planned to use both in vitro and
in vivo approaches to explore the biologic function(s) of MTDH in osteosarcoma progression
and metastasis. Further, we wished to elucidate the mechanism(s) underlying the metastasispromoting activity of MTDH, which are very likely to have impacts beyond osteosarcoma.
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Prior work on MTDH mechanisms have largely focused on its direct involvement in
classical oncogenic pathways so that protein-level interactions have been scarcely studied.
Currently, the means by which MTDH enhances cancer metastasis remain unclear. As
mentioned earlier, Brown and Ruoslahti proposed that the cell surface MTDH contains an
extracellular lung-homing domain which facilitates lung metastasis by binding to an
unknown ligand on pulmonary endothelial cells (63). However, our preliminary data in a
colon cancer cell line indicated that MTDH might regulate metastasis by modulating cell
attachment to ECM components, which is completely independent of endothelial cell binding.
One major goal of this research is to identify the potential MTDH-interacting protein(s) in
ECM. Characterization of the association between MTDH and ECM component will help us
gain better understanding of the metastasis-promoting function of MTDH and at the same
time provide novel target(s) for developing anti-metastasis therapy. More importantly, the
new findings will be applicable to a broad panel of invasive solid tumors with MTDH
overexpression and therefore would benefit more patients.
Combining our preliminary results and current knowledge about the functions of
MTDH in cancer, we hypothesize that MTDH overexpression promotes osteosarcoma cell
migration and invasion in response to recognition of non-cellular protein component of ECM
(Figure 3).
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Figure 3

Figure 3. Hypothesis: MTDH interacts with specific extracellular ECM component to
facilitate tumor cell invasion and migration in osteosarcoma.
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Chapter 2. Materials and Methods
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Cell lines and reagents
Human osteosarcoma cell lines HOS, CCHD, SAOS2, LM7, SJSA, MG63 were
maintained in High Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen)
supplemented with L-glutamine and 10% Fetal Bovine Serum (FBS) (Hyclone) in a
humidified atmosphere at 37°C with 5% CO2. The established osteosarcoma cell lines HOS,
SAOS2, SJSA, and MG63 are available from ATCC. LM7, a subline of SAOS2 with high
metastatic potential, was developed by repeated passaging of SAOS2 cells through
pulmonary metastases in nude mice (97). CCHD is a stable OS cell line derived from pretreatment biopsy of a proximal femur lesion in an 18-year-old male patient who presented
with pulmonary metastases at M. D. Anderson Children’s Cancer Hospital. The human fetal
osteoblastic cell line hFOB (ATCC) was cultured at 34°C with 5% CO2 in a 1:1 mixture of
phenol-free Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium with 2.5 mM Lglutamine (DMEM-F12) (Invitrogen), supplemented with 10% FBS and 0.3 mg/ml G418.
Patient Samples
Formalin-fixed, paraffin-embedded tissue blocks (FFPE) of osteosarcoma cases were
obtained from the files of the Department of Pathology, University of Michigan Medical
Center, Ann Arbor, MI. The University of Michigan Institutional Review Board provided a
waiver of informed consent to obtain these samples. After pathological review, a tissue
microarray was constructed from the most representative area using the methodology of
Nocito et al. (98). Each case was represented by two 1 mm or three 0.6 mm diameter cores,
obtained from the most representative, non-necrotic area of the tumor. The osteosarcoma
TMA containing primary tumor specimens from 49 patients and metastatic tumor specimens
from 24 patients was used to evaluate the expression level of MTDH in osteosarcoma with

18

immunohistochemistry (IHC). All specimens were reviewed by Dr. Wei-Lien Wang, an
experienced sarcoma pathologist at M.D. Anderson Cancer Center. Scoring of the tumor
samples was based on IHC staining intensity (as shown in Fig.7), and the intensity of the
signal was classified as 0 (no expression), 1 (weak expression), 2 (moderate expression) or 3
(strong expression).
Western blotting
Whole cell lysates from a panel of human osteosarcoma cell lines and normal human
osteoblast cells were prepared as follows: Cells were detached from the culture plates with
the aid of cell scrapers and washed with cold PBS. After 10-minute centrifugation at 13,000
rpm, cell pellets were resuspended and incubated in cold lysis buffer (25mM Tris-HCl pH 7.4,
150mM NaCl, 1mM EDTA, 1% NP-40 and 5% glycerol) with protease inhibitor cocktail
tablets (Roche Diagnostics) and phosphatase inhibitor cocktail 2 (Sigma) at 4°C for 20
minutes. Lysates were collected after being centrifuged at 13,000 rpm for 10 minutes. The
protein concentrations were determined using the bicinchoninic acid (BCA) assay (Thermo
Scientific). Whole-cell lysates were separated by SDS-PAGE on a 10% polyacrylamide gel
and transferred to nitrocellulose membrane following standard procedures. To detect MTDH
protein level, membrane was probed with rabbit-anti-MTDH antibody (1:1,000; SigmaAldrich), followed by horseradish peroxidase-conjugated anti-rabbit IgG (1:2,000; GE
Healthcare). Beta-actin (Sigma-Aldrich) was probed as a loading control. Chemiluminescent
signal was detected using Pierce ECL western blotting substrate (Thermo Scientific).
Real-time quantitative PCR
Total RNA was extracted from osteosarcoma cells with the RNeasy Mini Kit (Qiagen).
cDNA was made using the Omniscript Reverse Transcriptase Kit (Qiagen) with oligo-dTs
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(Invitrogen) according to the manufacturer's instruction. Real-time PCR analysis was
performed by the iCycler iQ quantitative PCR system (Bio-Rad) using SYBR Green PCR
Master Mix (Bio-Rad) following the protocol of the manufacturer. The primers used were as
follows: MTDH (Forward) 5’-CACTGTCAATGGAGGAGGCT-3’; MTDH (Reverse) 5’TGAACGGTCACTCCAACTCC-3’; GAPDH (Forward) 5’GCATCCTGGGCTACACTGAG-3’; GAPDH (Reverse) 5’CCACCACCCTGTTGCTGTAG-3’. Expression data were normalized to GAPDH
expression in each sample and were analyzed according to the 2-ΔΔ Ct method. The fold
changes in gene expression were calculated relative to the mRNA level of the control cell
line hFOB.
Flow cytometry
To measure the cell surface expression of MDTH, a panel of osteosarcoma cells were
detached from culture plates by enzyme-free cell dissociation buffer (Invitrogen) and washed
with cold PBS/1% bovine serum albumin (Fisher Scientific). The cells were incubated with
normal rabbit IgG (1:100; Millipore) or rabbit anti-MTDH antibody (1:100; Sigma-Aldrich)
on ice for 1 hour. The cells were then washed with PBS/1% BSA three times and blocked
with PBS/1% BSA containing 10% goat serum. Cells were then incubated with PEconjugated anti-rabbit IgG (1:50; Molecular Probes) on ice for 30 minutes and washed as
above. Expression was then assessed using a FACSCaliber flow cytometer (BD Biosciences)
and analyzed with Flowjo software (Tree Star Inc).
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Retroviral transduction
To silence human MTDH gene, four pGFP-V-RS shRNA retroviral constructs
(Origene) were used to generate 29-mer short hairpin RNAs (shRNA) targeting MTDH. The
shRNA sequences for MTDH are:
SH-3: 5’-GAAATCAAAGTCAGATGCTAAAGCAGTGC-3’
SH-4: 5’-TGCTGAGCCAGTTTCTCAGTCTACCACTT-3’
SH-5: 5’-CATCACAGTTACCACCGAGCAACTTACAA-3’
SH-6: 5’-GGTGATTCTCATCTAAATGTTCAAGTTAG-3’
To generate retrovirus, Phoenix-Ampho cells (ATCC) were seeded in 6-well plates at a
density of 1 million cells per well without antibiotics. After 12 hours, FuGENE 6 transfection
reagent (Roche) was diluted in serum-free DMEM to generate 100 µl solution (90 µL
DMEM and 10 µL FuGENE 6). After a 5-minute incubation, 3 µg of pGFP-V-RS vectors
containing MTDH shRNA or scrambled control sequence were added to the diluted FuGENE
6 transfection reagents and co-incubated at room temperature for 30 minutes. Next, the
transfection components were added to the cells and the culture plates were returned to the
incubator. The transfection complex was removed and replaced with fresh DMEM at 12
hours after initial transfection. After 24 hours, medium containing virus was collected and
centrifuged at 1500 rpm for 5 minutes. 2 ml of viral supernatant and 8 µg/ml Polybrene
(Sigma) were combined and added to HOS and CCHD cells. The plates were centrifuged at
2500 rpm for 50 minutes and then incubated at 34°C overnight. Viral medium was replaced
by fresh medium and cells were returned to standard culture conditions. After being selected
for puromycin resistance for 7 days, the stably transduced cells were analyzed by western
blot for MTDH protein expression, and knockdown was confirmed by densitometric analysis
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(Image J Processing Software, NIH). Cells transduced with SH-4 and SH-6 displayed the
highest MTDH knock-down efficiency, and therefore were used in parallel with cells
transduced with scrambled control plasmid in subsequent assays as indicated in individual
experiments.
Cell proliferation assay
Cells were seeded in triplicate into 6-well plates at the density of 2x104 and 5x104
cells/well respectively for HOS and CCHD cell lines. The number of viable cells was
counted after 2, 4, and 6 days of culture by using an automated Vi-Cell Analyzer (Beckman
Coulter). Cells were prepared as follows: medium was removed from the culture plates and
the cells were rinsed with PBS to remove the dead cells and debris. Cells were co-incubated
with 0.5 ml of 0.01 M HEPES/0.015 M MgCl2 buffer at room temperature for 5 minutes.
Next, 50 µl of 0.132 M Bretol (Ethylhexadecyldimethylammonium bromide) with 0.525 M
glacial acetic acid was added to the cells and the culture plates were agitated for 10 minutes
at room temperature. Cells were then fixed by the fixative solution (0.9% NaCl and 0.5%
formalin). 2 ml of the solution containing cell nuclei was transferred into an autosampler cup
for further processing by the automated Vi-Cell Analyzer.
Matrigel invasion assay
The invasive ability of osteosarcoma cells was evaluated by using 24-well BD BioCoat
Matrigel invasion chambers with 8-μm pore size (BD Biosciences). Briefly, 2x104 or 5x104
cells suspended in 300 µl of serum-free DMEM medium were seeded in triplicate into the
upper chamber of the system. The lower chamber contained 750 µl DMEM medium with 10%
FBS as a chemoattractant. In the antibody-blocking experiments, rabbit-anti- MTDH
antibody (Simga-Aldrich) or normal rabbit IgG (Millipore) were used at a final concentration

22

of 7.5 µg/ml to treat HOS and CCHD cells during the incubation period. After 48h
incubation at 37°C, the migrated cells were fixed, stained with Hema-3 (Fisher Diagnostics),
and counted under a microscope at 100-fold magnification.
Cell migration assay
In vitro cell migration was performed in the 24-well Corning Transwell polycarbonate
membrane cell culture inserts with 8-μm pore size (Corning). The 3x104 cells suspended in
100 μl serum-free DMEM were seeded into the upper part of each chamber, whereas the
lower compartments were filled with 600 μl of DMEM with 10% FBS. Normal rabbit IgG
(Millipore) and rabbit-anti-MTDH antibody (Sigma-Aldrich) at a final concentration of 7.5
µg/ml were used in the antibody-blocking experiments. After incubation for 24 h at 37°C, the
migrated cells were fixed, stained with Hema-3, and counted under a microscope at 100-fold
magnification.
Animal Model
To be sure that in vivo experiments were not compromised by growth of contaminating
non-transduced cells, clones were made from the MTDH shRNA #4 and scrambled control
CCHD cells described above by limiting dilution and visual confirmation of clonality.
Several were tested, and a clone whose growth characteristics matched the bulk population
most closely was chosen for in vivo experiments. These cells were then retrovirally labeled
with firefly luciferase as described (99). Luciferase-labeled CCHD cells (1×106 cells
suspended in 15μl of sterile PBS) were injected into the right tibia of 6-week-old
NOD/SCID/IL2Rγ-deficient mice (Jackson Laboratories). Primary tumor growth and
development of metastasis were monitored weekly through noninvasive bioluminescent
imaging using an IVIS 100 animal imaging system (Xenogen). Mice were sacrificed at 6
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weeks after inoculation, the lungs inflated with 10% formaldehyde via transtracheal injection,
and the primary tumors and lungs fixed in formalin and embedded in paraffin. Five micron
sections were mounted on glass slides for analysis, and H&E staining was performed by our
core laboratory. Metastatic nodules in lungs were quantified by direct microscopic
visualization and counting of a single lung section and confirmed by an experienced sarcoma
pathologist. All animal experiments were approved by the Institutional Animal Care and Use
Committee.
Immunohistochemistry
Immunohistochemistry was performed using formalin-fixed, paraffin-embedded tissue
sections. Heat Induced Epitope Retrieval (HIER) was performed on paraffin-embedded
tissues with 0.1M Sodium Citrate buffer, pH 6.0. After being blocked with 4% fish gelatin in
PBS for 20min, sections were incubated with rabbit-anti-MTDH antibody (1:300; SigmaAldrich) in a humidified chamber at 4°C overnight. Slides were incubated with rabbit-onrodent HRP-polymer (Biocare) or Mach 4 HRP polymer (Biocare) for 30min at room
temperature and staining was developed using DAB followed by Hematoxylin
counterstaining. Images were analyzed using a Leica light microscope.
Immunofluorescence
Osteosarcoma cells were seeded in 4-well Lab-Tek chamber slides (Nunc) at a density
of 1x105 cells per well in standard tissue culture conditions. Medium was removed after 12
hours and cells were fixed in -20°C acetone and 1:1 acetone and chloroform mixture for 5
minutes each. Cells were blocked with 4% fish gelatin in PBS and incubated with rabbitanti-MTDH antibody (1:300; Sigma-Aldrich) in a humidified chamber at 4°C overnight.
Slides were incubated with Alexa 488-labeled anti-rabbit secondary antibody (1:1,000,
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Molecular Probes) for 1h and nuclei were counterstained with Hoechst (1:10,000) for 5
minutes. Slides were mounted with anti-fade mounting media (glycerol/PBS containing Npropyl gallate) and a coverslip. Images were taken on a Nikon fluorescence microscope.
Cell adhesion assay
Cells were harvested, suspended in serum-free DMEM medium, and seeded in
triplicates (2x104 cells/well) onto 96-well plates pre-coated with Matrigel, Fibronectin,
Laminin, or Collagen-type IV (BD Biosciences). In the antibody-blocking experiments,
rabbit-anti- MTDH antibody (Sigma-Aldrich) or normal rabbit IgG (Millipore) were used at a
final concentration of 7.5 µg/ml to treat HOS and CCHD cells during the period of coincubation. After 1h incubation at 37°C in a humidified incubator containing 5% CO2,
unattached cells were removed by rinsing three times with PBS, Meanwhile, the input control
groups were left unwashed and the plates were centrifuged at 1300 rpm for 3min to force the
cells onto the bottom of the well. The remaining attached cells were fixed and stained with
Hema-3 (Fisher Diagnostics). The number of cells from three different fields of each well
was counted at 10X magnification. The percentage of adhesion was calculated by dividing
the average cell number of PBS-washed group with that of the respective input control group.
Co-Immunoprecipitation
To investigate whether MTDH interacts with extracellular Laminin through formation
of a protein complex, HOS cells were cultured under standard conditions until they reached
80-90% confluence and then treated with matrigel (1:100 dilutions) for 1h at 37°C. The cells
were then thoroughly washed with PBS to remove any unbound ECM components. Wholecell lysates were made and subjected to co-immunoprecipitation with anti-MTDH antibody
(Sigma-Aldrich), anti-Laminin antibody (Abcam), or normal IgG (Millipore) following
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manufacturer’s instructions. The precipitated proteins were then transferred to nitrocellulose
membrane and probed with anti-MTDH, anti-Laminin, and anti-Fibronectin (Abcam)
antibodies.
Statistical analyses
Triplicate samples were analyzed in each assay, and all experiments were conducted at
least three times. Data are represented as mean ± standard error of mean (SEM). Statistical
analysis was performed using two-tailed Student’s t test (GraphPad Software Inc). Log-rank
test was used for assessment of survival curves. A p-value of <0.05 was considered
statistically significant in all cases.
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Chapter 3: Elevated MTDH expression is associated with metastasis and poor outcome
in several cancers including osteosarcoma
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Rationale
As mentioned earlier, MTDH has been found to be widely upregulated in many types
of aggressive solid tumors and is often associated with poor survival (68, 70, 78, 80-83).
Accumulating evidence from functional studies of MTDH confirmed the importance of this
protein in many aspects of tumor growth and progression including metastasis (69, 77, 85).
To determine whether MTDH is involved in promoting metastasis in aggressive human
tumors, we started with analyzing the expression patterns of MTDH in microarray databases
of various cancer patients. We hypothesized that MTDH expression in distant metastases is
greater than that in primary tumors, and MTDH overexpression correlates with higher risk
for metastasis and worse survival in patients.
To obtain the relevant clinical information that contains survival and metastasis data,
we used publicly available cancer microarray databases (Oncomine, and R2: microarray
analysis and visualization platform) and osteosarcoma tissue microarray (a kind gift from Dr.
Dafydd G. Thomas, Department of pathology, the University of Michigan Hospitals and
Clinics, Ann Arbor, Michigan) to assess the correlation between MTDH expression and
clinical outcome in patients with breast cancer, prostate cancer, melanoma, and osteosarcoma.
Since MTDH has been rarely studied in osteosarcoma and the role of MTDH in
osteosarcoma metastasis remains unclear, we have concentrated our efforts in studying this
disease.
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Results
High MTDH expression is associated with metastasis and poor survival in multiple
aggressive human cancers
Analysis of MTDH mRNA levels in primary and metastatic lesions in two melanoma
datasets and one prostate cancer dataset revealed that metastatic lesions exhibited
significantly higher level of MTDH than primary tumors (1.8 fold in Haqq Melanoma,
p=0.005; 1.7 fold in Xu Melanoma, p=2.19E-6; and 3.9 fold in Chandran Prostate, p=1.75E10) (Figure 4). To determine whether MTDH expression is predictive of distant metastatic
relapse, we compared the MTDH mRNA level in primary tumor samples obtained from
patients who developed metastasis during the 3-year follow-up period versus those who did
not. Significantly higher level of MTDH (4.1 fold difference, p=1.25E-5) was observed in
patients who progressed to metastatic relapse, indicating that MTDH overexpression is
closely related to high metastatic potential of melanoma (Figure 5). In three independent
datasets, we further explored the relationship between MTDH expression and clinical
outcome in patients with melanoma and breast cancer (Figure 6). Analysis of stage III
melanoma patient data indicated that MTDH overexpression is correlated with shorter
survival from metastasis. Significantly shortened overall survival and metastasis-free survival
were observed in the high MTDH-expressing group as compared to the low MTDHexpressing group in breast cancer patients. These results imply that MTDH is overexpressed
in metastasis and may serve as an important prognostic marker of metastasis risk and survival
for cancer patients.
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Figure 4

Figure 4. MTDH expression is elevated in metastatic lesions. Comparison of MTDH
mRNA levels between unpaired primary tumors and metastatic lesions was performed in two
independent melanoma datasets (5 primary samples and 15 metastatic samples in Haqq
Melanoma dataset; 31 primary samples and 52 metastatic samples in Xu Melanoma dataset)
and one prostate cancer dataset (10 primary samples and 21 metastatic samples). All datasets
were accessed through the Oncomine Research Edition (https://www.oncomine.org).
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Figure 5

Figure 5. MTDH overexpression is associated with high incidence of metastatic relapse.
Comparison of MTDH mRNA expression levels between the patients with and without
newly developed metastatic lesions during follow-up period was performed in Laurent
melanoma dataset (19 samples total). Melanoma dataset was accessed through the Oncomine
Research Edition (https://www.oncomine.org).

31

Figure 6

Figure 6. High MTDH expression is associated with poor clinical outcome in melanoma
and breast cancer patients. Kaplan-Meier survival analysis was used to assess the
prognostic significance of MTDH in overall survival and metastasis-free survival of patients
with melanoma and breast cancer. Melanoma and breast cancer datasets were accessed
through the Oncomine Research Edition (https://www.oncomine.org). The log-rank test was
used to calculate the p value.
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MTDH expression in patient-derived osteosarcoma samples
To evaluate the expression of MTDH in primary and metastatic lesions of
osteosarcoma, a tissue microarray containing 49 primary tumor samples and 24 metastatic
tumor samples were examined by IHC staining with anti-MTDH antibody. MTDH
expression level was reported to be very low in normal bone tissues (95), but we observed
substantial MTDH staining in patient-derived osteosarcoma samples (Figure 7). Among the
49 primary tumor samples, 18/49 (37%) had no detectable MTDH, 17/49 (35%) displayed
weakly positive staining, 10/49 (20%) were moderately positive, and the remaining 4
samples (8%) had strong MTDH expression. In comparison, the staining intensity for MTDH
was more abundant in metastatic tumor samples: only 3/24 (12%) scored negative, 9/24
(37%) were weakly positive, 10/24 (42%) were moderately positive and 2/24 (9%) displayed
strong staining of MTDH (Table 1).
IHC analysis of the MTDH expression levels in 9 pairs of matched primary
osteosarcoma and metastases revealed that metastatic lesions had a significant 2.5 fold
increase in average MTDH staining intensity in comparison with their primary tumor
counterparts (p<0.05, Figure 8). Of the 9 patients, 7 patients had increased MTDH expression
from primary to metastatic tumor, 1 patient had equal MTDH expression in primary and
metastatic tumor, 1 patient displayed decreased MTDH in metastatic lesions. Taken together,
these observations suggested that MTDH is overexpressed in the majority of osteosarcoma
samples. In addition, increased MTDH expression could be detected in metastatic lesions
compared with primary tumors.
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Figure 7
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Figure 7. MTDH is highly expressed in osteosarcoma patient samples. Representative
MTDH immunohistochemical staining images of human osteosarcoma tissue microarray
were taken using a Leica light microscope. Stacked histogram displayed here represents the
proportion of samples in which MTDH expression was negative, weak, moderate or strong,
per the scale shown in the top panel. All specimens were reviewed by an experienced
sarcoma pathologist at M.D. Anderson Cancer Center.

Table 1

MTDH Expression
n (%)
Expression Score

Primary Tumor

Metastatic Lesion

0

18 (37%)

3 (12%)

1

17 (35%)

9 (37%)

2

10 (20%)

10 (42%)

3

4 (8%)

2 (9%)

Total

49 (100%)

24 (100%)

Table 1. Summary of osteosarcoma tissue microarray immunostaining data. Expression
score: 0-negative expression, 1-weakly positive expression, 2-moderately positive expression,
3-strongly positive expression.
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Figure 8

Figure 8. MTDH expression increases from primary to metastatic tumors in
osteosarcoma. Comparison of MTDH expression between primary tumors and distant
metastatic lesions was conducted on paired samples obtained from 9 osteosarcoma patients.
Scoring of the tumor samples was based on IHC staining intensity. The expression score was
classified as 0 (negative expression), 1 (weak expression), 2 (moderate expression) or 3
(strong expression).
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Table 2

MTDH Expression
Patient ID
1
2
3
4
5
6
7
8
9
Mean Score

Expression Score
Primary Tumor
0
0
1
1
0
3
1
0
0
0.67

Metastatic Lesion
1
3
2
1
1
2
2
2
1
1.67

Table 2. Comparison of MTDH expression scores in paired samples from the
osteosarcoma tissue microarray. Expression score: 0-negative expression, 1-weakly
positive expression, 2-moderately positive expression, 3-strongly positive expression. Red
number represents increased MTDH expression score in metastatic lesion; black number
represents equal MTDH expression score in metastatic lesion; blue number represents
decreased MTDH expression score in metastatic lesion.
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MTDH overexpression correlates with metastasis and poor survival in osteosarcoma
patients
To further assess the correlation between MTDH expression and clinical outcomes of
osteosarcoma patients, Kaplan-Meier survival analyses were performed on pretreatment
diagnostic biopsies of 88 high-grade osteosarcoma patients. 19 samples from patients who
presented with metastasis at diagnosis were excluded from the analysis. The other 71 samples
were categorized into high (n=42) and low (n=29) MTDH-expressing groups according to
MTDH gene expression levels. Our results revealed that patients with high MTDH
expression had significantly poorer metastasis-free survival (p < 0.05) and relatively
decreased overall survival (p = 0.10) rate compared with the low MTDH-expressing group
(Figure 9). In this respect, MTDH may serve as an important prognostic biomarker of
metastasis risk and survival for patients with osteosarcoma. With the available online
resources, we also compared MTDH expression in tumor samples from patients who
developed metastatic disease within 5 years versus those who did not within the same time
frame. MTDH level was found to be significantly higher in the patients who developed
metastatic relapse within 5 years after initial diagnosis of osteosarcoma (Figure 10).
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Figure 9

Figure 9. High MTDH expression correlates with worse clinical outcome in genomic
screen of high-grade osteosarcoma samples. Kaplan-Meier survival estimates of
metastasis-free and overall survival were generated from the Kuijjer Mixed Osteosarcoma
Database - Cleton-Jansen Lab. The dataset was accessed through the R2: microarray analysis
and visualization platform (http://r2.amc.nl). The log-rank test was used to calculate
the p value.
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Figure 10

Figure 10. MTDH overexpression predicts high risk of metastasis in osteosarcoma.
Comparison of the MTDH expression in primary tumors between patients with and without
newly developed metastatic disease within 5 years after diagnosis was performed in the
Kuijjer osteosarcoma dataset (53 samples total). The dataset was accessed through the R2:
microarray analysis and visualization platform (http://r2.amc.nl).
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Summary
By comparing MTDH expression between primary and metastatic tumor samples in
melanoma, prostate cancer, and osteosarcoma, we confirmed that MTDH is upregulated
during the metastatic process. As shown in Figure 5 and 10, MTDH overexpression has been
associated with higher risk of metastatic relapse in melanoma and osteosarcoma. Our
survival analysis in Figure 6 and 9 further revealed that high MTDH expression accelerates
tumor progression and predicts shorter overall and metastasis-free survival in several
aggressive cancers including osteosarcoma. These observations are consistent with previous
findings that MTDH is a powerful marker for tumor aggressiveness and a predictor for poor
patient prognosis (68, 70, 78, 80-83). As depicted in Figure 8, the significant increase in
MTDH expression from primary to metastatic tumors in the same patient spurred our interest
in understanding the mechanisms by which MTDH causes more aggressive disease. All the
clinical evidence described in this chapter supported the significance of MTDH
overexpression in osteosarcoma metastasis and warranted further exploration in this disease
model.
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Chapter 4. MTDH is overexpressed on osteosarcoma cell surface as a type II
transmembrane protein
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Rationale
A strong correlation between high MTDH expression and distant metastasis has been
implicated in two independent osteosarcoma clinical datasets presented in Chapter 3. This
finding triggered our interest to further explore the function(s) of MTDH in osteosarcoma,
and particularly in osteosarcoma metastasis. To continue the functional studies of MTDH in
osteosarcoma cell models, we had to examine the expression status of MTDH in each of the
osteosarcoma cell lines included in this study through western blotting and real-time
quantitative PCR.
Another important goal of this chapter is to investigate the distribution of MTDH
protein in osteosarcoma cells through immunofluorescence microscopy because the
subcellular localization of a protein is tightly linked to its function. To date, there is still great
uncertainty and controversy over the potential localization of MTDH in cancer cells as some
studies showed cytoplasmic and perinuclear localizations of MTDH while others suggested
that MTDH primarily expressed inside the nucleus (60, 66, 69). In 2004, Brown and
Ruoslahti provided the first and only evidence that supports the cell-surface localization of
MTDH in a study about the role of MTDH in breast cancer metastasis (63). Considering the
significance of cell surface proteins in cancer, we proposed that MTDH is abundantly
expressed on the surface of osteosarcoma cells. Moreover, we wanted to use flow cytometry
to determine the transmembrane topology of MTDH in osteosarcoma since the localization of
the long C-terminal domain of MTDH would provide clues to better understand its functions
and the underlying mechanisms.
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Results
MTDH expression profile in various osteosarcoma cell lines
After MTDH overexpression was confirmed in osteosarcoma samples in chapter 3, we
wanted to explore the expression of MTDH in established osteosarcoma cell lines. We began
by assessing MTDH expression at the protein level. According to western blotting analysis,
MTDH protein was overexpressed in all 6 osteosarcoma cell lines in comparison with the
normal control hFOB cells: 16 fold increase in CCHD, 10 fold increase in LM7, 10 fold
increase in SAOS2, 15 fold increase in SJSA, 9 fold increase in HOS, and 11 fold increase
MG63 (Figure 11). In the meantime, real-time PCR analyses demonstrated that osteosarcoma
cell lines had upregulated MTDH at the level of transcription as well (Figure 12). Compared
to the normal control cell line hFOB, the mRNA expression of MTDH was increased by 10.6
fold, 1.8 fold, 2.5 fold, 3.5 fold, 2.1 fold, and 2.3 fold in CCHD, LM7, SAo2, SJSA, HOS,
and MG63 cell lines respectively.
Figure 11

Figure 11. MTDH expression is upregulated in osteosarcoma cells. The protein
expression of MTDH in normal human fetal osteoblastic cells (hFOB) and a panel of human
osteosarcoma cell lines was analyzed by Western blot. Beta-actin was used as a loading
control.
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Figure 12

Figure 12. MTDH is upregulated in osteosarcoma cells at the mRNA level. Relative
mRNA expression of MTDH in hFOB and indicated osteosarcoma cell lines was determined
by real-time PCR. Expression data were normalized with GAPDH. Fold change of gene
expression in each osteosarcoma cell line was relative to hFOB. *P≤0.05, **P≤0.01,
***P≤0.001 vs. hFOB cells. Bar graphs represent mean ± SEM.

Localization of MTDH in osteosarcoma cells
To determine the localization of MTDH in osteosarcoma cells, HOS and CCHD cells
were examined by immunofluorescence (IF) microscopy using anti-MTDH antibody and
Alexa 488-labeled secondary antibody (Figure 13). IF analysis of fixed and permeabilized
HOS and CCHD cells demonstrated diffuse cytoplasmic staining of MTDH. Concentrated
immunoreactivity for MTDH was also detected at the cell edges in both CCHD and HOS
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cells. No significant nuclear distribution could be found. These observations implied that
MTDH protein is primarily localized to the cytoplasm and cell membrane in osteosarcoma
cells.

Figure 13

Figure 13. Expression and localization of MTDH in osteosarcoma cells. Acetone-fixed
HOS and CCHD cells were stained with rabbit-anti-MTDH primary antibody followed by
Alexa 488-labeled anti-rabbit secondary antibody. Cell nuclei were counterstained with
Hoechst. Green fluorescence represents the immunoreactivity for MTDH. Blue fluorescence
represents staining of nuclei. All images were taken on a Nikon fluorescence microscope
under 100X magnification.
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Cell surface expression and membrane topology of MTDH in osteosarcoma cells
To confirm the cell surface localization of MTDH, we used flow cytometry to evaluate
the expression and topology of MTDH protein on the cell membrane. Antibodies specific for
amino acid residues 315-461 of MTDH protein were allowed to bind only to the outside of
non-permeabilized osteosarcoma cells, ensuring that any signal detected was from the outer
cell membrane. While normal hFOB cells had virtually no detectable cell surface MTDH
expression, all osteosarcoma cell lines assessed expressed abundant level of cell surface
MTDH protein (Figure 14). The results indicated that, in osteosarcoma at least, MTDH is
localized at the cell surface as a type II transmembrane protein with a short cytoplasmic Nterminal domain and a long extracellular C-terminal domain which could be involved in
potential interactions with extracellular components.
The type II topology of MTDH in osteosarcoma cells was further confirmed by western
blot analyzing phosphorylation of serine residues located on the C-terminal segment (Figure
15). While there were multiple proteomic studies that identify serine-phosphorylated peptide
fragments apparently derived from MTDH, we could not detect any phosphoserine signal in
our immunoprecipitated MTDH samples. This observation, contrary to previous findings
from multiple phosphorylation studies, suggested that the C-terminal domain of MTDH
which is rich in phosphorylation sites localizes to the extracellular space, indicating a type II
topology of MTDH protein in osteosarcoma cells.
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Figure 14

Figure 14. Cell surface expression and membrane topology of MTDH in osteosarcoma
cells. Cell surface expression of MTDH was assessed in non-permeabilized hFOB and six
osteosarcoma cell lines by flow cytometry using rabbit-anti-MTDH (315-461 a.a.) antibody
in combination with a secondary PE-conjugated antibody. Representative histograms are
shown.
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Figure 15.

Figure 15. Analysis of phosphorylation status of MTDH in osteosarcoma cells. Wholecell lysates of HOS cells were subjected to co-immunoprecipitation with anti-MTDH
antibody or normal IgG. The precipitated proteins (lane 1 and lane 2) and the whole cell
lysates (lane 3 and lane 4) were transferred to nitrocellulose membrane and probed with antiphosphoserine and anti-MTDH antibodies.
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Summary
In this chapter we explored the expression, localization, and topology of MTDH in
established osteosarcoma cell lines through multiple experimental approaches. We have
demonstrated through western blotting and real-time quantitative PCR that compared to
normal human osteoblasts, osteosarcoma cell lines ubiquitously expressed high level of
MTDH at both protein and mRNA levels. Immunofluorescence analysis of the distribution of
MTDH protein in HOS and CCHD cells displayed uniform cytoplasmic and cell membrane
localization. By performing flow cytometry analysis on non-permeabilized osteosarcoma and
control cells with an anti-MTDH antibody that targets the C-terminal domain of MTDH, we
confirmed the overexpression of MTDH on cell surface and demonstrated that MTDH is a
type II transmembrane protein in osteosarcoma cells. This topology was supported by further
evidence obtained from the analysis of MTDH phosphorylation status in HOS cells.
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Chapter 5. Inhibition of MTDH suppresses invasive properties of osteosarcoma cells
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Rationale:
Previous studies of clinical samples have established a positive correlation between
high MTDH expression level and poor patient prognosis (68, 70, 78, 80-83). The data
collected in Chapter 3 revealed a significant increase in MTDH expression in metastatic
lesions compared to primary tumors. In the meantime, high expression of MTDH has been
associated with increased risk of metastasis in osteosarcoma. Given the results presented in
Chapter 4 that MTDH is overexpressed in osteosarcoma cell lines as compared with normal
human osteoblasts, we hypothesized that MTDH expression promotes metastasis-associated
behaviors in osteosarcoma cells.
In this chapter, we wanted to investigate the function(s) of MTDH, particularly those
expressed on the cell surface, in osteosarcoma metastasis by assessing the impact of MTDH
inhibition on osteosarcoma cell proliferation, migration, and invasion in vitro. We planned to
use two different approaches to inhibit MTDH: silencing endogenous MTDH gene
expression by retrovirus-mediated shRNA, and blocking surface-bound MTDH with antiMTDH antibody. For the experiments performed in this chapter, we have chosen HOS and
CCHD cell lines, both of which have abundant expression of MTDH and are highly invasive
according to literature and previous studies conducted in our lab. We anticipated that MTDH
inhibition leads to decreased cell invasion and migration ability.
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Results
Knockdown of endogenous MTDH reduces proliferation in osteosarcoma cells
To examine the effects of MTDH downregulation on osteosarcoma cells, we used
retrovirus-mediated shRNA targeting MTDH to stably knock down MTDH expression in
osteosarcoma cell lines HOS and CCHD. After a week of selection by puromycin, the
knockdown efficiency of MTDH in each cell line was validated by western blotting analysis.
A significant reduction in MTDH protein level (80% and 90% in SH-4 and SH-6 respectively)
was observed in cells transduced with MTDH-specific shRNA constructs when compared
with the control cells transduced with a scrambled sequence (Figure 16).

Figure 16.

Figure 16. Retrovirus-mediated shRNA targeting MTDH effectively reduces MTDH
expression in HOS and CCHD cells. MTDH knockdown in HOS and CCHD was
confirmed by western blotting analysis of whole cell lysates extracted from control and
MTDH-knockdown osteosarcoma cells. (SC: scramble control; SH-4: MTDH-specific
shRNA construct #4; SH-6: MTDH-specific shRNA construct #6). Beta-actin was used as a
loading control. Densitometric analysis (Image J Processing Software, NIH) was applied to
calculate the knockdown efficiency.
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Next, we used an automated Coulter counter (Vi-Cell) to evaluate the effect of MTDH
silencing on the proliferation rate of HOS and CCHD cells for a period of 6 days (Figure 17).
MTDH depletion caused a modest reduction in cell yield of HOS cells on day 6 (p<0.01). We
also observed a significant decrease in proliferation of MTDH-knockdown CCHD cells
compared with control cells on day 4 and day 6 (p<0.001).

Figure 17

Figure 17. Downregulation of MTDH reduces cell proliferation in osteosarcoma cells.
Cell proliferation was determined by automated cell counting after 0, 2, 4, and 6 days of
incubation of control cells (NC) and MTDH-knockdown cells (shMTDH-4 and shMTDH-6).
Results are shown as mean ± SEM of three replicates and they are representative of three
independent experiments.
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Downregulation of MTDH has marginal effect on clonogenic ability of osteosarcoma
cells
To determine whether MTDH knockdown alters clonal growth of osteosarcoma cells,
we performed colony formation assay on control and MTDH-knockdown HOS and CCHD
cells. When compared to the control HOS cells (137.3±4.3 colonies), a minor decrease in
the number of colony formed was observed in HOS-SH-4 cells (114.0±7.1 colonies, p<0.05)
while no significant reduction was found in HOS-SH-6 cells (130.3±7.9 colonies, ns).
Similar results were shown in CCHD cells. CCHD-SH-4 cells (288.7±9.6 colonies, p<0.05)
and CCHD-SH-6 cells (240.0±5.3 colonies, p<0.001) formed slightly fewer colonies than
the control CCHD-NC cells (332.7±6.6 colonies). These results indicated that MTDH
expression has very limited effect on clonogenic ability of osteosarcoma cells.
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Figure 18.

Figure 18. MTDH knockdown slightly decreases the colony formation ability of
osteosarcoma cells. Control and MTDH-knockdown HOS and CCHD cells were seeded in
6-well plates at very low density in triplicates and cultured under standard conditions. After 2
weeks of incubation, cells were fixed and stained with 0.05% crystal violet PBS solution.
Colonies with 50 or more cells were counted. Results are shown as mean ± SEM of three
replicates. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control cells.
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MTDH knockdown inhibits osteosarcoma cell migration and invasion
To explore the functional role of MTDH in osteosarcoma metastasis, we used transwell
migration assay and matrigel invasion assay to examine the effects of MTDH knockdown on
cell aggressiveness. It has been shown that downregulation of MTDH by shRNA triggered a
significant reduction in the number of migrated cells of HOS and CCHD after 24 hours when
compared to control cells (HOS: 429.3±7.0 cells/field in SH-4 and 310.0±80.5 cells/field in
SH-6 vs. 1201.0±98.4 cells/field in NC; CCHD: 128.7±39.7 cells/field in SH-4 and 107.7
±22.1 cells/field in SH-6 vs. 402.3±73.7 cells/field in NC) (Figure 19). We have also
demonstrated in both HOS and CCHD cells that efficient knockdown of MTDH, compared to
scrambled control shRNA, resulted in profound reduction in invasive ability of osteosarcoma
cells in vitro (HOS: 135.0±32.8 cells/field in SH-4 and 163.7±10.4 cells/field in SH-6 vs.
565.0±43.7 cells/field in NC; CCHD: 18.7±0.7 cells/field in SH-4 and 16.7±4.1 cells/field
in SH-6 vs. 216.0±31.9 cells/field in NC) (Figure 20). Taken together, these data strongly
suggested that MTDH promotes osteosarcoma aggressiveness by mediating cell invasion and
migration.
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Figure 19
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Figure 19. Silencing endogenous MTDH inhibits migration of HOS and CCHD cells. In
vitro cell migration was performed in the 24-well Corning Transwell polycarbonate
membrane cell culture inserts with 8-μm pore size (Corning). After incubation for 24 hours,
the migrated cells were fixed, stained with Hema-3, and counted under a microscope.
Representative pictures (right) and quantification of migrated cells (left) from transwell
migration assays are displayed. Results are shown as mean ± SEM (cells/field) of three
replicates and are representative of three independent experiments. *P≤0.05, **P≤0.01,
***P≤0.001 vs. control cells.
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Figure 20
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Figure 20. Downregulation of MTDH leads to decreased invasive ability of
osteosarcoma cells. The invasive ability of osteosarcoma cells was evaluated by using 24well BD BioCoat Matrigel invasion chambers with 8-μm pore size. After 48h incubation, the
penetrated cells were fixed, stained with Hema-3, and counted under a microscope
Representative pictures (right) and quantification of penetrated cells (left) from matrigel
invasion assays are shown. Results are shown as mean ± SEM (cells/field) of three replicates
and are representative of three independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs.
control cells.
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Blockade of cell surface MTDH with antibody inhibits migration and invasion
Since we have defined the cell-surface localization for MTDH in chapter 4, we wished
to know if steric interference with MTDH’s extracellular functions might cast a similar effect.
Transwell migration and matrigel invasion assays were performed on HOS and CCHD cells
in the presence of an anti-MTDH antibody specific for an epitope within the extracellular Cterminal domain compared to an isotype control antibody. A significant reduction in
migration was demonstrated in both HOS and CCHD cells incubated with the MTDHblocking antibody when compared with cells treated with the control IgG (HOS: 197.0±20.0
cells/field in anti-MTDH group vs. 994.0±92.0 cells/field in normal IgG group; CCHD:
304.0±7.0 cells/field in anti-MTDH group vs. 688.0±33.9 cells/field in normal IgG group)
(Figure 21). Results from the invasion assay revealed that blocking cell surface MTDH with
anti-MTDH antibody effectively decreased in vitro invasiveness of HOS and CCHD cells
(HOS: 95.3±25.2 cells/field in anti-MTDH group vs. 299.0±49.2 cells/field in normal IgG
group; CCHD: 138.7±17.3 cells/field in anti-MTDH group vs. 345.0±51.0 cells/field in
normal IgG group) (Figure 22).
To determine whether the effects on cell migration and invasion from anti-MTDH
antibodies resulted from antibody-induced cellular cytotoxicity, cell viability was evaluated
under the exact same conditions. Anti-MTDH antibody did not affect cell viability at the
indicated concentration within the same period of time (Figure 23). Taken together, these
results suggested that MTDH located on the cell surface is essential for mediating cell
motility and invasiveness in osteosarcoma.
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Figure 21
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Figure 21. Inhibition of cell surface MTDH leads to significantly decreases motility of
osteosarcoma cells. HOS and CCHD cells were co-incubated with rabbit IgG or rabbit-antiMTDH antibody at a final concentration of 7.5 µg/ml. After 24-hour of incubation in the
transwell Boyden chamber, the migrated cells were fixed, stained with Hema-3, and counted
under a microscope. Representative pictures (right) and quantification of migrated cells (left)
from migration assay are displayed. Results are shown as mean ± SEM (cells/field) of three
replicates and are representative of three independent experiments. *P≤0.05, **P≤0.01,
***P≤0.001 vs. control cells.
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Figure 22
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Figure 22. Anti-MTDH antibody inhibits osteosarcoma cell invasiveness. HOS and
CCHD cells were co-incubated with rabbit IgG or rabbit-anti-MTDH antibody at a final
concentration of 7.5 µg/ml. After 48-hour of incubation in the invasion chamber, the
penetrated cells were fixed, stained with Hema-3, and counted under a microscope.
Representative pictures (right) and quantification of penetrated cells (left) from invasion
assay are displayed. Results are shown as mean ± SEM (cells/field) of three replicates and
are representative of three independent experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs.
control cells.
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Figure 23

Figure 23. Anti-MTDH antibody has no significant impact on osteosarcoma cell
proliferation at indicated concentration. HOS and CCHD cells were co-incubated with
rabbit IgG or rabbit-anti-MTDH antibody at a final concentration of 7.5 µg/ml. After 48-hour
of incubation under standard culture conditions in a 6-well plate, cell yield was determined
by automated cell counting using Vi-Cell. Results are shown as mean ± SEM of three
replicates and are representative of three independent experiments.
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Summary
In this chapter we investigated the biological significance of MTDH in the aggressive
behavior of osteosarcoma. The impacts of MTDH knockdown on osteosarcoma cell
proliferation, colony formation, migratory and invasive abilities were tested by shRNAmediated gene silencing in HOS and CCHD cells. In the MTDH knockdown studies, we have
shown that downregulation of MTDH had limited effect on the proliferative and clonogenic
ability of osteosarcoma cells. However, we observed a more significant reduction in
transwell migration and matrigel invasion of MTDH-knockdown cells compared with the
control cells. To further understand the function(s) of MTDH located on the cell surface, we
used an anti-MTDH antibody which targets the extracellular C-terminal domain to interfere
with MTDH’s extracellular functions and assessed its impacts on osteosarcoma cell
migration and invasion. We have shown that blocking MTDH expressed on the cell
membrane significantly decreased osteosarcoma cell motility and effectively inhibited cell
invasion through matrigel. Altogether, these results indicate that MTDH plays a pivotal role
in mediating pro-metastatic activities in osteosarcoma cell models.
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Chapter 6. Knockdown of MTDH inhibits pulmonary metastasis in vivo
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Rationale:
Given the results presented in Chapter 5 that MTDH knockdown decreases the invasive
properties of osteosarcoma cells in vitro, we thus decided to evaluate the role of MTDH in
osteosarcoma metastasis in an animal model. Since high MTDH expression promotes
osteosarcoma cell migration and invasion, and is associated with increased risk of metastasis
in clinical datasets, we anticipated that MTDH knockdown would decrease the metastatic
potential of osteosarcoma cells and therefore inhibit pulmonary metastasis in vivo.
To better mimic the whole processes of tumor progression and metastasis, we
developed a novel bioluminescent orthotopic osteosarcoma xenograft murine model with
CCHD cells. The stable MTDH-knockdown and scrambled control CCHD cells were labeled
with luciferase and injected into the tibia of 6-week-old NOD/SCID/IL2Rγ-deficient mice.
Primary tumors were allowed to develop, followed by spontaneous pulmonary metastases.
Both the primary tumor and the lung metastases were monitored weekly by IVIS spectrum
imaging system and the luciferase signals were quantified. After the 6-week incubation
period, all mice were sacrificed and lungs were resected for further analysis.
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Results
MTDH knockdown impedes primary tumor growth and inhibits pulmonary metastasis
While in vitro analyses are helpful in determining a protein’s role in specific behaviors
like proliferation, migration and invasion, assessment of metastasis requires in vivo analysis.
To determine whether MTDH expression is essential for metastasis, we utilized luciferaselabeled CCHOD cells, transduced with either the same MTDH-specific shRNA used in
Chapter 5 or scrambled control shRNA. To ensure that our results were not compromised by
contamination with untransduced cells, which might have an advantage in both proliferation
and metastatic potential, clonal populations were derived from both the MTDH-knockdown
and scrambled control cells. One clonal line from each group was used for all in vivo studies.
One million tumor cells were injected into the tibia of each NOD/SCID/IL2Rγ-/xenograft host mouse (n=7 of MTDH-knockdown and control groups) and tumor growth was
measured weekly by bioluminescence imaging. Quantification of the bioluminescent signals
indicated that MTDH knockdown impeded primary tumor growth (Figure 24B) and inhibited
development of spontaneous lung metastases (Figure 24C). All mice in the control group
developed massive lung metastases 6 weeks after cancer cell inoculation, and some mice
demonstrated multiple metastatic sites including bones, livers, and kidneys (Figure 24A). By
contrast, mice in the MTDH-knockdown group had smaller primary tumors and significantly
fewer lung metastases. Three mice showed no evidence of metastatic disease and the other
four mice developed 5 or fewer metastatic lesions. Both primary and metastatic tumor burden
of the control group was remarkably higher than that of the MTDH-knockdown group.
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Figure 24

Figure 24. Knockdown of MTDH reduces primary tumor growth and inhibits
pulmonary metastasis. A) Displayed are images of representative mice at the fourth week
after injection. Primary tumor and lung metastasis burden of NOD/SCID/IL2Rγ-deficient
mice inoculated orthotopically with luciferase-labeled CCHD cells with or without MTDH
knockdown were monitored weekly by bioluminescent imaging. Quantification of the
bioluminescent signals emitted from primary tumor (A) and lung metastases (B) are shown.
Each data point represents mean ± SEM of 7 mice.
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Tumor-bearing mice from both groups were sacrificed at 6 weeks after inoculation and
the mouse lungs were harvested, photographed, and weighed. Microscopic examination of
the H&E stained lung sections revealed that downregulation of MTDH significantly
decreased the number of metastatic nodules developed in lung (Figure 25).

Figure 25

Figure 25. Downregulation of MTDH inhibits lung metastasis in vivo. Image of whole
lungs isolated from mice sacrificed at six weeks after tumor cell inoculation (top).
Representative H&E stained lung sections of mice at the sixth week after intratibial injection
of one million CCHD-NC or CCHD-shMTDH cells (bottom).
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Further analysis of the resected mouse lungs revealed that the mean lung weight
(p<0.05, Figure 26A) and the mean number of metastatic nodules (p<0.0001, Figure 26B)
were remarkably reduced in the MTDH-knockdown group. The mean lung weight of mice
inoculated with MTDH-knockdown cells was 23% less than that of the control group. In the
meantime, an average of 11.29±1.52 metastatic tumor nodules were detected per field in
lungs isolated from the control group, while mice in the MTDH-knockdown group developed
an average of 0.51±0.26 metastatic nodules per field.

Figure 26

Figure 26. MTDH knockdown decreases lung tumor burden and reduces the number of
metastatic nodules. A) Whole lungs isolated from mice sacrificed at the sixth week post
injection were weighed. Data are displayed as a scatter dot blot. B) Quantified lung
metastases are depicted as the number of metastatic nodules per field in a scatter dot blot.
Lines and whiskers represent mean ± SEM of 7 mice.
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To be certain that the reduction in metastasis was not solely due to the reduced
proliferation of primary tumors, a parallel group of mice (n=3) inoculated with MTDHknockdown cells were allowed to live to 12 weeks after initial inoculation, during which time
the primary tumors reached a size comparable to that of the control group near the
termination of the experiment while no sign of lung metastasis was detected through
bioluminescent imaging (Figure 27). When their lungs were analyzed, no metastatic nodule
was identified. Hence, the low rate of metastasis observed in the MTDH-knockdown group
was due to the substantially reduced metastatic capacity of these cells.
Figure 27

Figure 27. Inhibition of metastasis observed in MTDH-knockdown group is due to
decreased metastatic ability of osteosarcoma cells. Quantification of the bioluminescent
signals emitted from primary tumor (A) and lung metastases (B) are shown here. Each data
point represents mean ± SEM of 7 mice in control group and 3 mice in CCHD-shMTDH
group.
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Metastasized osteosarcoma cells have upregulated MTDH expression
Immunohistochemical analysis of primary and metastatic tumors harvested from mice
of control and MTDH-knockdown groups demonstrated that MTDH expression was
dramatically enhanced in pulmonary metastatic nodules in comparison to that in primary
tumors (Figure 28). When we examined the tissue samples from the four mice that developed
lung metastasis in MTDH-knockdown group, we found that the rare metastatic nodules
demonstrated re-expression of MTDH, while MTDH expression was still suppressed in
primary tumors.
Figure 28

Figure 28. Metastasized osteosarcoma cells display upregulated MTDH expression.
Representative examples of MTDH-immunostaining intensity in primary tumors and lung
metastases are shown here. Images of higher magnification are displayed in the bottom left
corner.
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Summary
Based on conclusion from Chapter 5 that MTDH promotes osteosarcoma cell migration
and invasiveness in vitro, we hypothesized that knockdown of MTDH would inhibit
pulmonary metastasis of osteosarcoma in vivo. To test this hypothesis, we used non-invasive
bioluminescence imaging to investigate the role of MTDH in tumor progression and
metastasis in an orthotopic osteosarcoma xenograft mouse model.
By comparing the intensity of bioluminescent signal emitted from tibia and lung
between control mice and the mice inoculated with stable MTDH-knockdown cells, we
demonstrated that downregulation of MTDH in osteosarcoma cells delayed primary tumor
growth and inhibited pulmonary metastasis in vivo. Further analysis of the resected lungs
revealed that MTDH knockdown decreased metastatic tumor burden and significantly
reduced the number of metastatic nodules developed in lung.
Additionally, immunohistochemical analysis of primary tumor and lung sections from
experimental animals revealed that osteosarcoma cells that have successfully metastasized to
the lung demonstrated upregulated MTDH level. This observation is consistent with the
patient data (Figure 8) obtained from osteosarcoma tissue microarray analysis presented in
Chapter 3. It is worth mentioning that rare pulmonary metastases of mice bearing MTDHknockdown tumors had re-expressed MTDH despite arising from a clonal population
expressing shRNA specific for MTDH. Although the mechanism by which aggressive
osteosarcoma cells overcome shRNA-mediated gene silencing is unknown, this finding
suggested a pivotal role of MTDH in promoting osteosarcoma metastasis.
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Chapter 7. MTDH modulates cell adhesion to ECM through interaction with Laminin
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Rationale
Through functional, in vivo analyses, we have clearly demonstrated in previous
chapters that knocking down endogenous MTDH by shRNA inhibits osteosarcoma invasion
and metastasis. More importantly, MTDH expressed on the cell membrane has been found to
play an essential role in mediating osteosarcoma cell invasiveness as our results showed that
steric interference of the extracellular domain of MTDH by anti-MTDH antibody
significantly decreased cell motility and inhibited cell invasion through matrigel. Since
invading through the extracellular matrix is a prerequisite for tumor cell metastasis, these
observations led us to reason that surface-bound MTDH mediates interaction and signal
transduction between tumor cells and non-cellular protein components of the extracellular
matrix (ECM), which facilitates cell motility and invasive properties.
To search for extracellular binding partners for MTDH, a series of adhesion assays
were performed to evaluate the adhesion ability of osteosarcoma cells with or without
MTDH inhibition to major components of ECM, including Fibronectin, Collagen, and
Laminin. After we identified the candidate MTDH-interacting protein, we performed bidirectional co-immunoprecipitation to confirm the interaction. Whole cell lysates of HOS
cells cultured in standard conditions or briefly treated with diluted matrigel were subjected to
anti-MTDH immunoprecipitation, followed by SDS-PAGE separation and western blotting.
By identifying this novel connection between MTDH and ECM, we wished to establish a
new paradigm for the function of MTDH in mediating tumor cell metastasis.
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Results
MTDH mediates osteosarcoma cell adhesion to ECM protein Laminin
To determine whether MTDH is involved in modulation of cell adhesion to ECM, we
performed a set of adhesion assays on 96-well plates pre-coated with matrigel and different
ECM proteins, comparing control and MTDH-knockdown cells (Figure 29). HOS and CCHD
cells with downregulated MTDH displayed a significantly decreased adhesion to matrigel
and Laminin compared with their control counterparts. However, there were no statistically
significant differences in adhesion to Fibronectin and Collagen IV in both HOS and CCHD
cell lines.
Since we showed that cell-surface MTDH plays a pivotal role in promoting cell
invasion, we next investigated whether blocking the cell surface-bound MTDH with antibody
affected the ability of osteosarcoma cells to adhere to the ECM proteins (Figure 30). MTDHspecific antibody decreased adhesion of HOS cells to matrigel, Laminin, and Fibronectin by
approximately 70%, 80%, and 20% respectively as compared with that observed in the
control cells treated with normal IgG (Figure 30A). Similar results were seen with CCHD
cells, with 70%, 90% and 50% reduction in cell attachment to matrigel, Laminin, and
Fibronectin in the presence of MTDH-blocking antibody (Figure 30B). Meanwhile, adhesion
of the two cell lines to Collagen IV was not significantly altered by anti-MTDH antibody.
These results suggested that the surface-bound MTDH plays a key role in mediating adhesion
of cancer cells to the ECM. This effect seemed likely to be achieved through interaction with
Laminin, which is a major component of the basement membrane (100).
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Figure 29
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Figure 29. Downregulation of MTDH decreases osteosarcoma cell adhesion to matrigel
and Laminin. HOS (A) and CCHD (B) cells were harvested, suspended in serum-free
DMEM medium, and seeded in triplicate onto 96-well plates pre-coated with Matrigel,
Fibronectin, Laminin, or Collagen IV. After 1-2h incubation, unattached cells were removed
by rinsing three times with PBS while the input control groups were left unwashed.
Histograms represent the percentage of cells remaining bound to each substrate compared to
unwashed controls. Data represent mean ± SEM of three replicates from independent
experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control cells.
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Figure 30.
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Figure 30. Blocking cell surface MTDH inhibits osteosarcoma cell adhesion to matrigel
and Laminin. HOS (A) and CCHD (B) cells were treated with rabbit anti-MTDH antibody
or normal rabbit IgG at a final concentration of 7.5µg/ml. After 1-2h incubation in 96-well
plates pre-coated with Matrigel, Fibronectin, Laminin, or Collagen IV, unattached cells were
removed by rinsing three times with PBS while the input control groups were left unwashed.
Histograms represent the percentage of cells remaining bound to each substrate compared to
unwashed controls. Data represent mean ± SEM of three replicates from independent
experiments. *P≤0.05, **P≤0.01, ***P≤0.001 vs. control cells.
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Identification of Laminin as an MTDH-interacting protein
To validate the interaction between MTDH and extracellular Laminin, we performed
bi-directional co-immunoprecipitation (co-IP) experiments with antibodies targeting these
two proteins. Whole cell lysates extracted from HOS cells cultured under standard conditions
or exposed briefly to diluted matrigel were subjected to immunoprecipitation with antiMTDH antibody. Western blot analysis with anti-Laminin antibodies demonstrated that
Laminin could only be detected in the cells pre-treated with diluted matrigel (Figure 31).
Reciprocal co-IP was performed with anti-Laminin antibody. Western blotting of the
immunoprecipitated protein complex with anti-MTDH antibody indicated that MTDH was
pulled down along with Laminin from the cells co-incubated with diluted matrigel (Figure
32). These results suggest that MTDH and Laminin sustain a strong protein-protein
interaction in osteosarcoma cell model.
To determine the specificity of the interaction between MTDH and Laminin, we
investigated the potential connection between MTDH and Fibronectin which is another major
protein component of ECM. Whole cell lysates from control cells or cells co-incubated with
diluted matrigel were subjected to anti-MTDH co-IP and probed with anti-Fibronectin
antibody in western blot. We could not detect Fibronectin being co-immunoprecipitated with
MTDH in this experiment (Figure 33). These data indicate that MTDH located on the cell
surface regulates cell-matrix adhesion by interacting with extracellular Laminin, thus having
a key role in promoting invasiveness and metastasis.
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Figure 31

Figure 31. Identification of Laminin as MTDH-interacting partner. Lysates from HOS
cells without exposure to matrigel (lane 1 and lane 2) or HOS cells briefly exposed to
extracellular matrix proteins contained in matrigel (lane 3 and lane 4) were
immunoprecipitated with anti-MTDH antibody or normal rabbit IgG, and immunoblotted
with anti-Laminin antibody. Input control displayed at the bottom represents the protein level
of MTDH and Laminin in each sample before co-IP. IP: immunoprecipitation; WB: western
blot.
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Figure 32

Figure 32. MTDH is pulled down with Laminin in the same protein complex in a co-IP
experiment. Lysates from HOS cells without exposure to matrigel (lane 1 and lane 2) or
HOS cells briefly exposed to extracellular matrix proteins contained in matrigel (lane 3 and
lane 4) were immunoprecipitated with anti-Laminin antibody or normal rabbit IgG, and
immunoblotted with anti-MTDH antibody. Input control displayed at the bottom represents
the protein level of MTDH and Laminin in each sample before co-IP. IP:
immunoprecipitation; WB: western blot.
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Figure 33

Figure 33. MTDH has no evident interaction with Fibronectin in ECM. Lysates from
HOS cells without exposure to matrigel (lane 1 and lane 2) or HOS cells briefly exposed to
extracellular matrix proteins contained in matrigel (lane 3 and lane 4) were
immunoprecipitated with anti-MTDH antibody or normal rabbit IgG, and immunoblotted
with anti-Fibronectin antibody. Input control displayed at the bottom represents the protein
level of MTDH and Fibronectin in each sample before co-IP. IP: immunoprecipitation; WB:
western blot.
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Summary
In this chapter we hypothesized that MTDH expressed on the cell surface modulates
cell-ECM interactions by binding to non-cellular ECM proteins. We propose that the proteinprotein interaction between surface-bound MTDH and extracellular ECM proteins promotes
tumor cell adhesion to ECM, therefore facilitating cell migration and invasion through ECM
and basement membrane barriers. To test this hypothesis and identify the candidate
interacting-partner of MTDH, we evaluated cell adhesive ability to matrigel and various
ECM protein components in HOS and CCHD cells with constitutive MTDH knockdown or
blockade of MTDH at the cell surface, followed by a bi-directional co-IP.
Through a series of cell adhesions assays, we observed significantly decreased cell
adhesion to matrigel and Laminin in MTDH-knockdown osteosarcoma cell lines as
compared to control osteosarcoma cells after 1-2 hours of incubation time. Interestingly,
MTDH-knockdown cells showed very little difference in cellular adhesive ability to
Fibronectin and Collagen IV when compared to the control cells. Similarly, we saw a
remarkable reduction in cellular adhesion to marigel and Laminin for HOS and CCHD cells
treated with antibodies targeting the extracellular domain of MTDH in relation to the control
cells co-incubated with equal concentrations of normal IgG. A modest decrease in adhesion
to Fibronectin was observed in the antibody-blocking experiments while no difference was
detected in cell adhesion to Collagen IV. These results suggest that Laminin could be the
candidate protein involved in the interaction between cell surface MTDH and the ECM. Bidirectional co-IP with anti-MTDH antibody and anti-Laminin antibody confirmed that these
two proteins exist in the same protein complex and sustain a strong protein-protein
interaction. The fact that Fibronectin, another major component of ECM, could not be co89

immunoprecipiated with MTDH supported the specificity of the interaction between MTDH
and Laminin. By establishing this novel connection between MTDH and extracellular
Laminin, our research not only confirms the importance of the cell surface localization of
MTDH in osteosarcoma, but also provides a mechanism that is involved in the metastasispromoting actions of MTDH.
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Chapter 8. Discussion: Implications of Results and Future Directions
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Implications of Results
Accumulating evidence suggests that the aberrant MTDH expression observed in many
malignant tumors is often correlated with poor clinical outcomes (68, 70, 78, 80-83). The
critical role of MTDH in tumor cell proliferation, chemoresistance, angiogenesis, invasion
and metastasis has been verified by a number of functional studies performed in various
cancer models (63, 69, 70, 73, 74, 77, 78, 84, 85, 90). However, most of the recent studies
about MTDH focus exclusively on common adult cancers such as breast cancer and liver
cancer. There was no report on expression status of MTDH in osteosarcoma when we started
this project. Since the most common cause of mortality associated with osteosarcoma is
pulmonary metastasis, identification and characterization of new molecular targets for the
development of anti-metastasis therapeutic strategies will be valuable for treating this disease.
Moreover, the mechanism of how MTDH mediates tumor cell aggressiveness and metastasis
remained largely unknown. To extend our understanding of the biological functions of
MTDH and to identify novel therapeutic targets for osteosarcoma, we established three
objectives for our research: 1) investigating the expression pattern of MTDH in osteosarcoma
patient samples and its relationship to metastatic risk and patients’ outcome in clinic; 2)
identifying the function(s) of MTDH in tumor progression and metastasis of osteosarcoma; 3)
elucidating the mechanism(s) by which MTDH mediates tumor aggressiveness. To achieve
these three goals, we conducted a series of studies using clinical datasets and specimens,
osteosarcoma cell models, and an orthotopic osteosarcoma xenograft mouse model. In the
present study we have shown that MTDH, a cell surface protein correlated with worse
outcome in osteosarcoma and many other cancers, plays a decisive role in multiple steps of
tumor metastasis.
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MTDH is widely expressed in osteosarcoma and correlates with metastasis
We have demonstrated that MTDH is highly expressed in both osteosarcoma cell lines
and patient tumor specimens. Western blot and Q-PCR analyses of a panel of six
osteosarcoma cell lines and the normal control cell line derived from human fetal osteoblasts
revealed that osteosarcoma cells had upregulated MTDH expression both at the protein and
mRNA levels (Figure 11 and 12 ). Evaluation of MTDH expression in a tissue microarray
containing 73 osteosarcoma samples showed that MTDH could be detected in 63% of
primary osteosarcoma tumors and 88% of metastatic tumors specimens (Figure 7 and Table
1). More importantly, after examining IHC staining intensities of MTDH in 9 matched pairs
of primary and metastatic osteosarcoma specimens, we found that MTDH expression was
remarkably increased from primary to metastatic tumors in the same patient (Figure 8 and
Table 2). Similarly, we observed in three other clinical datasets of melanoma and prostate
cancer that metastatic tumor lesions had significantly higher level of MTDH expression than
primary tumor specimens (Figure 4)
In support of this notion, analyses of survival data and related clinical outcomes in
melanoma and breast cancer datasets revealed that patients with high MTDH expression
developed metastatic disease earlier and had a shorter overall survival than the low-MTDH
group (Figure 5 and 6). Comparative analysis of metastasis-free survival in a cohort of highgrade osteosarcoma patients has also demonstrated that MTDH overexpression correlated
with a higher risk of metastatic relapse and is associated with worse clinical outcome (Figure
9 and 10). These results strongly indicated that MTDH may act as a metastasis-promoting
gene in various cancers including osteosarcoma, and could be an ideal prognostic biomarker
for predicting osteosarcoma metastasis. The fact that the trend toward reduced overall
93

survival in the MTDH-high cohort did not reach statistical significance probably reflects the
small sample size (n=71 total). The analysis should be repeated with a larger number of
clinical samples when they become available for osteosarcoma.
MTDH promotes osteosarcoma metastasis by modulating cell motility and invasiveness
The biological process of invading and filtrating into the surrounding ECM and the
basement membrane is the first step of cancer metastasis. Therefore, the metastatic potential
of a tumor cell is usually dependent on its motility and invasive ability. Previous studies in
glioma and head and neck squamous cell carcinoma have demonstrated that MTDH promotes
proteolytic digestion of the connections between tumor cells and ECM through activation of
the MMPs including MMP1, MMP2 and MMP9 (70, 71, 84). Our data are consistent with
recent findings in other tumor models showing that MTDH promotes metastatic
dissemination of tumor cells through modulating cell migration and invasion.
Both in vitro and in vivo studies clearly demonstrated that blocking MTDH is an
effective way to inhibit the metastatic process, at least in these osteosarcoma models.
Silencing endogenous MTDH by shRNA abrogated in vitro migration and invasion of human
osteosarcoma cells without severely affecting their proliferation and clonogenic ability
(Figure 17-20). In vivo experiments performed in an osteosarcoma mouse model of
spontaneous pulmonary metastasis demonstrated that constitutive knockdown of MTDH
delayed primary tumor growth and inhibited pulmonary metastasis (Figure 24-26). In
addition, we saw a remarkable increase in MTDH expression in metastatic lesions in the lung
as compared to the primary tumors resected from the mouse tibia (Figure 28), which is
similar to what has been observed in clinical osteosarcoma samples (Figure 8). Overall our
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data indicated a key role of MTDH in inducing the invasive properties in osteosarcoma cells.
These findings have important clinical implications because MTDH, as a pivotal metastasisassociated gene overexpressed in osteosarcoma, could be an ideal molecular target for
preventing and treating metastatic disease.
Functional significance of the cell surface localization of MTDH
Regarding the mechanism by which MTDH mediates metastasis, Brown and Ruoslahti
had proposed that cell-surface MTDH contains an extracellular lung-homing domain which
mediates pulmonary metastasis by binding to an unknown ligand specifically expressed on
lung endothelial cells (63). This report was the first to indicate the importance and potential
functions of MTDH expressed on the surface of tumor cells. By using flow cytometry with
an antibody reactive to amino acid residues 315-461 on the C-terminal segment of MTDH,
we confirmed that MTDH localizes to the cell surface and has type II membrane topology in
osteosarcoma (Figure 14 and 15). Our data demonstrated that osteosarcoma cells displayed
abundant level of MTDH on cell surface as compared to the control osteoblasts (Figure 14).
It is known that cell-surface proteins are often involved in mediating interactions
between cells and its microenvironments. The cell-surface localization of MTDH in
osteosarcoma provided revealing clues about its function and narrowed down the list of
potential proteins that it may interact with. Through a series of in vitro functional studies, we
have demonstrated that the cell surface distribution of MTDH is critical for its metastasispromoting function in osteosarcoma. Steric interference of the biological functions of the cell
surface MTDH with antibodies targeting the extracellular C-terminal segment could
efficiently inhibit cell migration, invasion, and adhesion to the ECM. Altogether, our
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preliminary data in osteosarcoma cell models indicated that the invasion-promoting functions
of surface-bound MTDH are independent of endothelial cell binding, which is inconsistent
with the model proposed in Brown and Ruoslahti’s paper that MTDH contains an
extracellular lung-homing domain.
MTDH functions as a cell surface receptor for Laminin
The processes of invasion and metastasis involve a complex cascade of events. One
important property of metastatic tumor cells is the ability to attach to and migrate through
basement membranes which comprise barriers against invading cells. Tremendous effort has
been made in the past to define the role of proteases in degrading tumor matrix and
surrounding tissue planes, but the mechanisms underlying tumor cell recognition, attachment
to, and manipulation of these non-cellular stromal components remain incompletely
characterized.
Through a set of cell adhesion assays using osteosarcoma cells transduced with
MTDH-specific shRNA or scrambled control sequence, we found that inhibition of
endogenous MTDH resulted in significantly decreased adhesion to marigel and Laminin in
vitro, while cell attachment to Fibronectin and Collagen IV was not affected (Figure 29).
Similar effects were observed when we blocked the surface-bound MTDH with the antiMTDH antibodies (Figure 30). Considering the fact that matrigel is a gelatinous mixture of
ECM proteins that resembles the complex extracellular microenvironment, MTDH may serve
as an important mediator of cell-ECM interactions. The impaired cell adhesion to Laminin
observed when MTDH was inhibited further suggested that Laminin could be the
extracellular binding partner of MTDH. This hypothesis was validated by the bi-directional
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co-immunoprecipitation performed with anti-MTDH and anti-Laminin antibodies, which
demonstrated that MTDH and Laminin exist in the same protein complex when tumor cells
interact with ECM (Figure 31 and 32). Our current study provides the first evidence that
MTDH is a key regulator of cell-matrix adhesion in osteosarcoma, through which cell
motility and invasiveness could be directly affected. Moreover, we have identified MTDH as
a novel cell-surface interacting partner for extracellular Laminins. It will be of future interest
to determine the region of MTDH that mediates binding with Laminin, which will enable
better characterization of this interaction.
Laminins, a family of secreted glycoproteins, are major components of extracellular
matrix and basement membranes (100). They are composed of three different subunits, the αchain, β-chain, and γ-chain arranged in a cruciform shape (101). Laminins could form
independent protein networks through connections with other ECM proteins such as
Collagen IV, Enactin, Fibronectin, and Perlecan (102). They could also interact with cells
through binding with the cell surface proteins including integrin receptors and various
glycoproteins (102). Through these interactions, Laminins have diverse biological functions
including promoting cell adhesion and migration, initiating cell signaling pathways, and
mediating cell differentiation and polarity (103). The significance of Laminin in tumor
metastasis is well characterized (104). There is further evidence in osteosarcoma supporting a
positive relationship between cell invasiveness and its ability to attach to Laminin (105, 106).
By discovering the new connection between MTDH and extracellular Laminin in
osteosarcoma, we improve our understanding of the mechanisms by which MTDH promotes
metastasis. More importantly, these findings will establish a new paradigm for the function
of MTDH in mediating tumor cell invasiveness. It is known that cancer cells need to invade
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through basement membranes multiple times during their metastatic spread: starting with
initial escape from the primary tumor, followed by intravasation and extravasation at
secondary sites (107). For osteosarcoma, like many solid tumors, the spreading process also
involves invasion into adjacent soft tissues and muscles. By incorporating this information
into our present findings, here we propose a new model for the function of MTDH in
metastasis (Figure 34).

Figure 34. Schematic model of MTDH function. In the upper left panel, a mass of tumor
cells (blue) is seen extending via mass migration through extracellular matrix proteins and
stromal elements toward a nearby blood vessel. Laminin, normally present predominantly in
the basement membrane, is depicted just outside endothelial cells. MTDH mediates
attachment to the basement membrane and orients the migration of cells toward the vessel.
In the lower left panel, tumor cells have breached the endovascular space and access the
bloodstream. On the right, the upper panel depicts lungs with metastatic tumors, and the
lower panel depicts how MTDH-Laminin interactions might help mediate exit from the
endovascular space once the pulmonary endothelial lining is disrupted.
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Figure 34
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Future Directions
Mechanistic Studies
Since we have identified the connection between MTDH and Laminin when tumor
cells interact with the extracellular microenvironments, alternative strategies for blocking the
interactions between MTDH and Laminin may provide additional approaches for preventing
metastatic progression in addition to targeting MTDH itself. Further mechanistic studies to
define the protein domain structures, interactions and functions of MTDH are warranted. Our
next step will be to determine if this interaction is governed by a direct physical association
or mediated by another protein located on the cell surface or inside the ECM. To address this
question, fluorescence resonance energy transfer (FRET) microscopy or bimolecular
fluorescence complementation (BiFC) could be employed to display whether a close physical
association between MTDH and Laminin exists in osteosarcoma.
Future experiments will include mapping the specific protein domain on MTDH that is
responsible for binding with extracellular Laminins through a series of protein truncation and
site mutagenesis approaches. We are currently collaborating with the Center for
Biomolecular Structure and Function of MD Anderson Cancer Center to develop purified
protein fragments of MTDH. We propose to test each of these protein fragments for their
ability to block the binding of osteosarcoma cells to Laminin. We will then use smaller
fragments of the portion that blocks the binding to map out the region on MTDH that
mediates the binding of the whole molecule to Laminin. These results will provide grounds
for the development of therapeutic strategies that interferes with the interaction between
MTDH and ECM. In the meantime, we plan to perform a yeast two-hybrid screening with
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full-length MTDH cDNA and cDNA library from human osteosarcoma cell to identify
potential intracellular MTDH-interacting proteins.
We recognize that the interaction between MTDH and Laminin might be mediated by
other cell-surface proteins or ECM constituents. Previous studies have shown that integrins, a
family of integral membrane glycoproteins that mediate cell-cell and cell-ECM interactions,
are the most common receptors for Laminins in various cell systems (108). The α, β, and γchains of Laminin have all been shown to possess integrin-binding sites (108). Clustering of
integrins on cell surface has been shown to promote adhesion, migration, invasion, and
survival of tumor cells both in vitro and in vivo in a variety of human cancers (109-111).
Knowing the essential function of integrins in tumor malignancy and their close association
with Laminins, we want to investigate whether integrins are involved in the interaction
between MTDH and Laminin. Since the expression pattern of integrins in osteosarcoma
remains unclear, we will determine the expression level of various integrins in osteosarcoma
cells by q-PCR and western blot, followed by co-immunoprecipitation experiments to study
the association among MTDH, Laminins, and integrins.
Translational Implications
Our results collectively suggest that overexpression of cell-surface protein MTDH
promotes metastasis in osteosarcoma. The therapeutic potential of manipulating MTDH is
highlighted by the fact that the overall expression of this protein is dramatically upregulated,
not only in osteosarcoma as shown here, but also in many other solid tumors (60, 63, 65, 7077). More importantly, by identifying its cell surface localization we have provided
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promising evidence that this protein will be easily accessible to therapeutic agents, which
strongly supports the development of targeted therapies against MTDH.
During the past 25 years, the therapeutic antibody technologies have undergone
considerable development (112). Chimeric, humanized, and completely human monoclonal
antibodies are gradually becoming important treatment options for cancer patients (113).
These monoclonal antibody products, either in unconjugated forms or linked to cytotoxic
molecules such as conventional chemotherapeutic agents, prodrug-converting enzymes,
radioisotopes, and natural toxins, could recognize cell surface antigens that are specifically
expressed on cancer cells and facilitate localized delivery and release of the toxic agents to
the tumor sites (114-116). With the aid from the activated host immune system, therapeutic
antibodies are able to induce a series of cytotoxic events such as cell cycle arrest and
apoptosis to achieve clinical responses (115). Due to the high specificity and efficacy of
antibody-based therapeutics, six types of these drugs have been approved by the FDA for the
treatment of cancer (112). Knowing that MTDH is localized to the cell membrane as a type II
transmembrane protein in osteosarcoma, its extracellular C-terminal segment which contains
510 amino acid residues could be an ideal target for antibody-based immunotherapy. We
expect the development of humanized monoclonal anti-MTDH antibody to improve the
current therapeutic regimens for osteosarcoma patients and extend their survival.
Another approach to target MTDH in clinic is to develop chimeric antigen receptor
(CAR)-based therapies. This novel type of immunotherapy which incorporates the exquisite
specificity of monoclonal antibodies with the long-term persistence of cytotoxic T cells has
shown clinically-significant anti-tumor activities in a number of adult and pediatric
malignancies (117, 118). In addition, current clinical trials in adults and pediatric patients
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have demonstrated that the CAR therapy has high specificity and limited off-tumor toxicity
for both short-term and long-term treatments (119-121). Since the efficacy of CAR therapy
depends on the affinity of T cells to tumor cell-surface antigens, an ideal targeted protein
should have abundant expression on the surface of tumor cells while having limited
expression on normal tissue. Considering the discrete overexpression of MTDH in numerous
cancer types, potential MTDH-targeted CAR therapy will have a wide range of applications
in treating solid tumors in which effective control of metastasis is pivotal in improving
clinical outcomes.
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